As of April 2024, unlike Wegovy, Ozempic is not approved for weight loss or treating obesity
[4] While observational and legacy data from the UKPDS study suggest potential cardiovascular benefits, metformin does not have proven cardiovascular outcome benefits in the same way as newer agents like GLP-1 receptor agonists or SGLT2 inhibitors
This includes identifying any underlying thyroid issues, hormonal imbalances, or previous experiences with weight loss medications
Smaller doses split twice weekly for fewer reported side effects and an easier adjustment period
However, as Dave Knapp from On The Pen discusses below, it may be a tough case for compounding pharmacies to explain why thousands of patients who received traditional compounded semaglutide previously ALL now need an adjusted version of the peptide
These are pulled verbatim from MeAgain's public App Store reviews